Asunto(s)
Amicacina/farmacología , Plaquetas/efectos de los fármacos , Heparina/farmacología , Inhibidores de Agregación Plaquetaria/farmacología , Agregación Plaquetaria/efectos de los fármacos , Trombocitopenia/diagnóstico , Antibacterianos/farmacología , Anticoagulantes/farmacología , Citratos/farmacología , Ácido Edético/farmacología , Reacciones Falso Positivas , Humanos , Recuento de Plaquetas/normas , Cultivo Primario de Células , Citrato de Sodio , Trombocitopenia/sangreRESUMEN
Successful HIV-1 infection requires a number of specific stages leading to integration of the provirus. We previously suggested that members of the VPAC neuroendocrine receptor family may play a role in HIV-1 infection. We now show that stimulation of the VPAC2 receptor with specific agonists provides strong resistance to HIV-1 infection. Daily stimulation of VPAC2, but not VPAC1 or PAC1, resulted in up to 90% inhibition of X4 or R5 productive infections in either cell lines or PBMCs. VPAC2 agonist stimulation had no effect on cell surface co-receptors, the rate of apoptotic cells, or HIV-1 entry or reverse transcription of viral RNA. However, we provide evidence that VPAC2-specific agonists inhibit HIV-1 infection through an inhibitory effect on the ability of the HIV-1 cDNA to integrate into the host DNA. These data reveal that VPAC2 agonists are appropriate candidates for further study as possible treatments aimed at the amelioration of HIV/AIDS.
Asunto(s)
Infecciones por VIH/virología , VIH-1/fisiología , Receptores de Tipo II del Péptido Intestinal Vasoactivo/agonistas , Integración Viral/fisiología , Apoptosis , Línea Celular , Células Cultivadas , Genes Reporteros , Proteína p24 del Núcleo del VIH/análisis , Humanos , Células Jurkat , Leucocitos Mononucleares/virología , Receptores del Polipéptido Activador de la Adenilato-Ciclasa Hipofisaria/agonistas , Receptores de Tipo I del Polipéptido Intestinal Vasoactivo/agonistas , Transcripción Reversa , Internalización del VirusRESUMEN
The seven-transmembrane (7TM) G-protein-coupled neuroendocrine receptors VPAC1 (HGNC approved gene symbol VIPR1) and VPAC2 (HGNC approved gene symbol VIPR2) are expressed in different tissues and involved in the regulation of important biological functions. We now report the identification and characterization of novel five-transmembrane(5TM) forms of both human VPAC1 and human VPAC2. These alternatively spliced variant mRNAs result from the skipping of exons 10/11, spanning the third intracellular loop, the fourth extracellular loop, and the transmembrane regions 6 and 7, producing in-frame 5TM receptors predicted to lack a G-protein-binding motif. RT-PCR showed that these 5TM receptors are differentially expressed in transformed and normal cells. Translation of the 5TM protein was demonstrated by transfection and expression in CHO cells. Following agonist stimulation, differential signaling of the 7TM versus 5TM forms was shown both for the activation of adenylate cyclase and for tyrosine phosphorylation. The identification of these splice variants in various cells and their expression and differential signal transduction compared to the 7TM form suggest that these novel receptors have biological relevance.